ViRexx Announces Collaboration With Defence Research And Development Canada-Suffield To Expand Chimigen"TM" Platform Technology For Use In Biodefense

Published: Mar 30, 2006

EDMONTON, Alberta--(BUSINESS WIRE)--March 31, 2006--ViRexx Medical Corp. (TSX:VIR)(AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that it has entered into a research collaboration with Defence Research and Development Canada - Suffield (DRDC Suffield) to carry out research on applying ViRexx's proprietary Chimigen(TM) vaccine platform for biodefense. This collaboration initiates key strategic research with the scientists at DRDC Suffield, Canada's leading biodefense establishment, to evaluate the use of the Chimigen(TM) vaccine platform for biodefense applications.

Back to news